JP2016503394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503394A5 JP2016503394A5 JP2015538468A JP2015538468A JP2016503394A5 JP 2016503394 A5 JP2016503394 A5 JP 2016503394A5 JP 2015538468 A JP2015538468 A JP 2015538468A JP 2015538468 A JP2015538468 A JP 2015538468A JP 2016503394 A5 JP2016503394 A5 JP 2016503394A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- disease
- group
- conjugate according
- neuropeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 claims 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108020004999 messenger RNA Proteins 0.000 claims 12
- 102000005962 receptors Human genes 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 108060002566 ephrin Proteins 0.000 claims 7
- 102000012803 ephrin Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 108010001789 Calcitonin Receptors Proteins 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 102100038842 Neuropeptide B Human genes 0.000 claims 4
- 102000028517 Neuropeptide receptor Human genes 0.000 claims 4
- 108070000018 Neuropeptide receptor Proteins 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 108010085094 neuropeptide B Proteins 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 108700011259 MicroRNAs Proteins 0.000 claims 3
- 108050001286 Somatostatin Receptor Proteins 0.000 claims 3
- 102000011096 Somatostatin receptor Human genes 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 102000004136 Vasopressin Receptors Human genes 0.000 claims 3
- 108090000643 Vasopressin Receptors Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims 2
- 102000055006 Calcitonin Human genes 0.000 claims 2
- 108060001064 Calcitonin Proteins 0.000 claims 2
- 102100038520 Calcitonin receptor Human genes 0.000 claims 2
- 102000010180 Endothelin receptor Human genes 0.000 claims 2
- 108050001739 Endothelin receptor Proteins 0.000 claims 2
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 claims 2
- 108010012048 Kisspeptins Proteins 0.000 claims 2
- 102000013599 Kisspeptins Human genes 0.000 claims 2
- 108010008364 Melanocortins Proteins 0.000 claims 2
- 102000017922 Neurotensin receptor Human genes 0.000 claims 2
- 108060003370 Neurotensin receptor Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108050000742 Orexin Receptor Proteins 0.000 claims 2
- 102000008834 Orexin receptor Human genes 0.000 claims 2
- 102000003141 Tachykinin Human genes 0.000 claims 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 2
- 229960004015 calcitonin Drugs 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 claims 2
- 239000002865 melanocortin Substances 0.000 claims 2
- ZRCUKBVXFDZBKP-XJEBPGRNSA-N neuropepetide s Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 ZRCUKBVXFDZBKP-XJEBPGRNSA-N 0.000 claims 2
- 108060008037 tachykinin Proteins 0.000 claims 2
- 229960003726 vasopressin Drugs 0.000 claims 2
- JCSUBZJLENMKRH-UHFFFAOYSA-N (2-chloro-4-methylphenyl)hydrazine;hydrochloride Chemical group [Cl-].CC1=CC=C(N[NH3+])C(Cl)=C1 JCSUBZJLENMKRH-UHFFFAOYSA-N 0.000 claims 1
- HWYCFZUSOBOBIN-AQJXLSMYSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-n-[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminome Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 HWYCFZUSOBOBIN-AQJXLSMYSA-N 0.000 claims 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 claims 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 claims 1
- 102000035037 5-HT3 receptors Human genes 0.000 claims 1
- 108091005477 5-HT3 receptors Proteins 0.000 claims 1
- 108091005435 5-HT6 receptors Proteins 0.000 claims 1
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 claims 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 claims 1
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 claims 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 1
- 108010004276 A18Famide Proteins 0.000 claims 1
- 108010060263 Adenosine A1 Receptor Proteins 0.000 claims 1
- 102000030814 Adenosine A1 receptor Human genes 0.000 claims 1
- 108010041368 Adenosine A2 Receptors Proteins 0.000 claims 1
- 102000000506 Adenosine A2 Receptors Human genes 0.000 claims 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims 1
- 102000009346 Adenosine receptors Human genes 0.000 claims 1
- 108050000203 Adenosine receptors Proteins 0.000 claims 1
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- 108050006749 Alpha 1A adrenoceptor Proteins 0.000 claims 1
- 108050008446 Alpha 1B adrenoceptor Proteins 0.000 claims 1
- 108050000241 Alpha 1D adrenoceptor Proteins 0.000 claims 1
- 102100024349 Alpha-1A adrenergic receptor Human genes 0.000 claims 1
- 102100024402 Alpha-1B adrenergic receptor Human genes 0.000 claims 1
- 102100024401 Alpha-1D adrenergic receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 101710085045 B2 bradykinin receptor Proteins 0.000 claims 1
- 108010051479 Bombesin Proteins 0.000 claims 1
- 102000013585 Bombesin Human genes 0.000 claims 1
- 108010073466 Bombesin Receptors Proteins 0.000 claims 1
- 108010044231 Bradykinin B1 Receptor Proteins 0.000 claims 1
- 102000010183 Bradykinin receptor Human genes 0.000 claims 1
- 108050001736 Bradykinin receptor Proteins 0.000 claims 1
- 108091005471 CRHR1 Proteins 0.000 claims 1
- 108091005470 CRHR2 Proteins 0.000 claims 1
- 108010061299 CXCR4 Receptors Proteins 0.000 claims 1
- 102000012000 CXCR4 Receptors Human genes 0.000 claims 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 claims 1
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 claims 1
- 102100024654 Calcitonin gene-related peptide type 1 receptor Human genes 0.000 claims 1
- 101710178048 Calcitonin receptor Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 claims 1
- 102000004859 Cholecystokinin Receptors Human genes 0.000 claims 1
- 108090001085 Cholecystokinin Receptors Proteins 0.000 claims 1
- 108010074311 Corticotropin Receptors Proteins 0.000 claims 1
- 102000036364 Cullin Ring E3 Ligases Human genes 0.000 claims 1
- 102000004076 Dopamine D1 Receptors Human genes 0.000 claims 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 claims 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 claims 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 102000050554 Eph Family Receptors Human genes 0.000 claims 1
- 108091008815 Eph receptors Proteins 0.000 claims 1
- 108010055211 EphA1 Receptor Proteins 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102000051096 EphA2 Receptor Human genes 0.000 claims 1
- 108010055191 EphA3 Receptor Proteins 0.000 claims 1
- 102000021607 EphA3 Receptor Human genes 0.000 claims 1
- 108010055179 EphA4 Receptor Proteins 0.000 claims 1
- 102000021727 EphA4 Receptor Human genes 0.000 claims 1
- 108010055336 EphB1 Receptor Proteins 0.000 claims 1
- 108010055334 EphB2 Receptor Proteins 0.000 claims 1
- 102000000075 EphB2 Receptor Human genes 0.000 claims 1
- 108010055325 EphB3 Receptor Proteins 0.000 claims 1
- 102000011652 Formyl peptide receptors Human genes 0.000 claims 1
- 108010076288 Formyl peptide receptors Proteins 0.000 claims 1
- 102100021261 Frizzled-10 Human genes 0.000 claims 1
- 102100039676 Frizzled-7 Human genes 0.000 claims 1
- 102100028466 Frizzled-8 Human genes 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 102000011392 Galanin receptor Human genes 0.000 claims 1
- 108050001605 Galanin receptor Proteins 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 claims 1
- 101000819451 Homo sapiens Frizzled-10 Proteins 0.000 claims 1
- 101000885797 Homo sapiens Frizzled-7 Proteins 0.000 claims 1
- 101001061408 Homo sapiens Frizzled-8 Proteins 0.000 claims 1
- 101001080225 Homo sapiens Hematopoietic SH2 domain-containing protein Proteins 0.000 claims 1
- 101001059802 Homo sapiens N-formyl peptide receptor 3 Proteins 0.000 claims 1
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 claims 1
- 101000634561 Homo sapiens Neuropeptide FF receptor 2 Proteins 0.000 claims 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 claims 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 1
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 claims 1
- 108090000950 Melanocortin Receptors Proteins 0.000 claims 1
- 102000004378 Melanocortin Receptors Human genes 0.000 claims 1
- 102000001419 Melatonin receptor Human genes 0.000 claims 1
- 108050009605 Melatonin receptor Proteins 0.000 claims 1
- 102100024930 Melatonin receptor type 1A Human genes 0.000 claims 1
- 101710098568 Melatonin receptor type 1A Proteins 0.000 claims 1
- 102100024970 Melatonin receptor type 1B Human genes 0.000 claims 1
- 101710098567 Melatonin receptor type 1B Proteins 0.000 claims 1
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 claims 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 1
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 claims 1
- 102100037283 Neuromedin-B receptor Human genes 0.000 claims 1
- 102100029409 Neuromedin-K receptor Human genes 0.000 claims 1
- 102400001090 Neuropeptide AF Human genes 0.000 claims 1
- 102400001095 Neuropeptide FF Human genes 0.000 claims 1
- 102000011015 Neuropeptide FF receptor Human genes 0.000 claims 1
- 108010061550 Neuropeptide FF receptor Proteins 0.000 claims 1
- 102100029049 Neuropeptide FF receptor 1 Human genes 0.000 claims 1
- 102100029050 Neuropeptide FF receptor 2 Human genes 0.000 claims 1
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 claims 1
- 102000012301 Neuropeptide Y receptor Human genes 0.000 claims 1
- 102000029748 Neuropeptide Y2 receptor Human genes 0.000 claims 1
- 102000028435 Neuropeptide Y4 receptor Human genes 0.000 claims 1
- 108010002245 Neuropeptide Y4 receptor Proteins 0.000 claims 1
- 102000028582 Neuropeptide Y5 receptor Human genes 0.000 claims 1
- 108010046593 Neuropeptide Y5 receptor Proteins 0.000 claims 1
- 101150056943 Npffr1 gene Proteins 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 claims 1
- 102100028139 Oxytocin receptor Human genes 0.000 claims 1
- 108090000876 Oxytocin receptors Proteins 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 101150043341 Socs3 gene Proteins 0.000 claims 1
- 101000757768 Strongylocentrotus purpuratus Aristaless homeobox protein Proteins 0.000 claims 1
- 102100037342 Substance-K receptor Human genes 0.000 claims 1
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 claims 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 claims 1
- 102000007124 Tachykinin Receptors Human genes 0.000 claims 1
- 108010072901 Tachykinin Receptors Proteins 0.000 claims 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 claims 1
- 102000008236 Toll-Like Receptor 7 Human genes 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 claims 1
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 claims 1
- 108010062475 Type 2 Angiotensin Receptor Proteins 0.000 claims 1
- 102000025309 Type 2 Angiotensin Receptor Human genes 0.000 claims 1
- 108010021430 Type 2 Melanocortin Receptor Proteins 0.000 claims 1
- 102000008318 Type 3 Melanocortin Receptor Human genes 0.000 claims 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 claims 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 101150062861 amy3 gene Proteins 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000001638 cerebellum Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 108700023159 delta Opioid Receptors Proteins 0.000 claims 1
- 102000048124 delta Opioid Receptors Human genes 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 210000001320 hippocampus Anatomy 0.000 claims 1
- 210000003016 hypothalamus Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims 1
- 210000001259 mesencephalon Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 102000051367 mu Opioid Receptors Human genes 0.000 claims 1
- 210000001577 neostriatum Anatomy 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 108010089579 neuropeptide Y2 receptor Proteins 0.000 claims 1
- 108060005714 orexin Proteins 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 108010055752 phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide Proteins 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 108010064556 somatostatin receptor subtype-4 Proteins 0.000 claims 1
- 101150029725 sst1 gene Proteins 0.000 claims 1
- 108020001588 κ-opioid receptors Proteins 0.000 claims 1
- 108020001612 μ-opioid receptors Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719297P | 2012-10-26 | 2012-10-26 | |
| EP12382413 | 2012-10-26 | ||
| EP12382413.8 | 2012-10-26 | ||
| US61/719,297 | 2012-10-26 | ||
| PCT/EP2013/072411 WO2014064258A1 (en) | 2012-10-26 | 2013-10-25 | Compositions and methods for selective delivery of oligonucleotide molecules to cell types |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503394A JP2016503394A (ja) | 2016-02-04 |
| JP2016503394A5 true JP2016503394A5 (https=) | 2016-12-22 |
Family
ID=47148689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538468A Pending JP2016503394A (ja) | 2012-10-26 | 2013-10-25 | 細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20140315795A1 (https=) |
| EP (1) | EP2911697A1 (https=) |
| JP (1) | JP2016503394A (https=) |
| AU (1) | AU2013336582A1 (https=) |
| CA (1) | CA2889608A1 (https=) |
| MX (1) | MX2015005328A (https=) |
| WO (1) | WO2014064258A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057179A2 (en) | 2002-01-11 | 2003-07-17 | Biomarin Pharmaceutical, Inc. | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| CA2796722C (en) | 2010-04-19 | 2021-06-01 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| CN103747807B (zh) | 2011-07-05 | 2016-12-07 | 比奥阿赛斯技术有限公司 | P97‑抗体缀合物和使用方法 |
| CN107115352B (zh) | 2011-08-04 | 2020-10-30 | 耶达研究及发展有限公司 | 微rna和包含微rna的组合物 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| CA3140358A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| EP2911695B1 (en) | 2012-10-26 | 2023-11-29 | Palomo Limited | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| AU2014243816B2 (en) | 2013-03-13 | 2019-01-31 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| JP6603227B2 (ja) | 2014-02-03 | 2019-11-06 | バイオアシス テクノロジーズ インコーポレイテッド | Ｐ９７融合タンパク質 |
| CA2936158C (en) | 2014-02-05 | 2023-06-13 | Yeda Research And Development Co. Ltd. | Use of mir-135 or precursor thereof for the treatment and diagnosis of a bipolar disease |
| DK3107562T3 (da) | 2014-02-19 | 2019-12-16 | Bioasis Technologies Inc | P97-ids-fusionsproteiner |
| AU2015252906C1 (en) * | 2014-05-01 | 2020-09-17 | Bioasis Technologies Inc. | p97-polynucleotide conjugates |
| WO2016004043A1 (en) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| US10733023B1 (en) * | 2015-08-06 | 2020-08-04 | D2Iq, Inc. | Oversubscription scheduling |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| GB2574525B (en) * | 2015-12-21 | 2020-09-02 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| KR20180112060A (ko) | 2016-02-23 | 2018-10-11 | 타베다 세라퓨틱스, 인코포레이티드 | Hsp90 표적화된 접합체 및 이의 입자 및 제형 |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| AU2019269066B2 (en) | 2018-05-18 | 2022-10-06 | F. Hoffmann-La Roche Ag | Targeted intracellular delivery of large nucleic acids |
| CN119264211A (zh) | 2018-08-27 | 2025-01-07 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CN109085709B (zh) * | 2018-09-29 | 2021-07-30 | 昆山龙腾光电股份有限公司 | 一种贴附组件及贴附系统 |
| US12478684B2 (en) | 2019-04-11 | 2025-11-25 | Northeastern University | Oligonucleotide-polymer miktoarm conjugates and methods of use |
| JP2022545555A (ja) * | 2019-08-28 | 2022-10-27 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 概日リズムの調節因子およびそれらの使用 |
| WO2023027125A1 (ja) * | 2021-08-24 | 2023-03-02 | ペプチドリーム株式会社 | ヒトトランスフェリンレセプター結合抗体－ペプチドコンジュゲート |
| WO2024069229A2 (en) | 2022-08-03 | 2024-04-04 | Sutura Therapeutics Ltd | Biologically active compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID18218A (id) | 1995-01-27 | 1998-03-19 | Novo Nordisk As | Senyawa dengan sifat-sifat pelepas hormon pertumbuhan |
| WO1997026270A2 (en) | 1996-01-16 | 1997-07-24 | Ribozyme Pharmaceuticals, Inc. | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules |
| US20040087530A1 (en) * | 1998-02-11 | 2004-05-06 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modulating leptin activity |
| GB0116878D0 (en) | 2001-07-11 | 2001-09-05 | Timestrip Ltd | Time indicator |
| US7323566B2 (en) | 2004-04-23 | 2008-01-29 | Filer Crist N | Radiopharmaceutical and methods of synthesis and use thereof |
| US20090149512A1 (en) | 2004-05-14 | 2009-06-11 | Novo Nordisk A/S | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases |
| EP1890716A2 (en) | 2005-06-16 | 2008-02-27 | Hadasit Medical Research Services & Development Co. Ltd. | Methods for the treatment of renal failure |
| EP1937066A4 (en) | 2005-08-18 | 2008-12-24 | Alnylam Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES |
| EP1996209B1 (en) | 2006-03-22 | 2015-11-04 | Starpharma Pty Limited | Contraceptive composition |
| US20100324113A1 (en) * | 2006-06-01 | 2010-12-23 | Sullenger Bruce A | Delivery Method |
| US8143222B2 (en) | 2007-10-22 | 2012-03-27 | Washington University | Modular platform for targeted therapeutic delivery |
| WO2009073809A2 (en) * | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US8796216B2 (en) * | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| US20110124706A1 (en) * | 2009-11-25 | 2011-05-26 | Zhigang He | SOCS3 Inhibition Promotes CNS Neuron Regeneration |
| CA2796722C (en) | 2010-04-19 | 2021-06-01 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
| WO2013183656A1 (ja) * | 2012-06-04 | 2013-12-12 | 大日本住友製薬株式会社 | Ｇタンパク質共役受容体結合リガンドと核酸分子とのコンジュゲート |
-
2013
- 2013-10-25 AU AU2013336582A patent/AU2013336582A1/en not_active Abandoned
- 2013-10-25 MX MX2015005328A patent/MX2015005328A/es unknown
- 2013-10-25 CA CA2889608A patent/CA2889608A1/en not_active Abandoned
- 2013-10-25 EP EP13783538.5A patent/EP2911697A1/en active Pending
- 2013-10-25 WO PCT/EP2013/072411 patent/WO2014064258A1/en not_active Ceased
- 2013-10-25 US US14/064,047 patent/US20140315795A1/en not_active Abandoned
- 2013-10-25 JP JP2015538468A patent/JP2016503394A/ja active Pending
- 2013-10-25 US US14/438,869 patent/US9938525B2/en active Active - Reinstated
-
2016
- 2016-11-23 US US15/360,195 patent/US20170073679A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503394A5 (https=) | ||
| CN114787357A (zh) | 用于编辑靶标rna的添加了功能性区域的反义型指导rna | |
| JP2021531022A5 (https=) | ||
| AU2014284836B2 (en) | Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease | |
| MX2009008508A (es) | Composiciones y m?todos para prevenir el c?ncer con cupredoxinas. | |
| JP2014509511A5 (https=) | ||
| JP2014504150A5 (https=) | ||
| JP2014518612A5 (https=) | ||
| JP2017093448A5 (https=) | ||
| JP2015522264A5 (https=) | ||
| JP2018512876A5 (https=) | ||
| TR201815415T4 (tr) | Fibroz tedavisi. | |
| JP2010540453A5 (https=) | ||
| US9586944B2 (en) | Specific targeting of RNA expanded repeat sequences | |
| WO2007056153B1 (en) | Peptide-dicer substrate rna conjugates as delivery vehicles for sirna | |
| Vo et al. | Building of neomycin–nucleobase–amino acid conjugates for the inhibition of oncogenic miRNAs biogenesis | |
| JP2018533956A5 (https=) | ||
| WO2019196887A1 (zh) | 一种新型小激活rna | |
| JP2014508161A5 (https=) | ||
| IL273578B1 (en) | Antibodies targeting pdl1 and methods of use thereof | |
| IL274508B1 (en) | GLP-1 receptor ligand residue fused to oligonucleotides and uses thereof | |
| CN105722979A (zh) | 肝癌相关的基因特异性siRNA、包含所述siRNA的双链寡RNA分子和包含它们的用于预防或治疗癌症的组合物 | |
| JP2013537404A5 (https=) | ||
| NZ604094A (en) | Double stranded rna compounds to rhoa and use thereof | |
| JP2017000155A (ja) | 線維症予防又は治療剤 |